Aires Pharmaceuticals Secures $20,000,000 Series B Round

  • Feed Type
  • Date
    11/12/2010
  • Company Name
    Aires Pharmaceuticals
  • Mailing Address
    4690 Executive Drive San Diego, CA 92121
  • Company Description
    As a first product opportunity, the Company is developing an inhaled drug that has been demonstrated in animal models to treat both adult and pediatric pulmonary hypertension. As a second product opportunity, Aires is also pursuing indications associated with the treatment of bacterial pulmonary infections.
  • Website
    http://www.airespharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Additionally, Aires further bolstered its cash reserves by entering into an agreement with Novartis International Pharmaceutical Limited whereby Novartis has been granted an exclusive option to acquire Aires following the successful completion of a Phase 2 clinical study of Aironite™ to treat pulmonary arterial hypertension.
  • M&A Terms
  • Venture Investor
    MPM Capital
  • Venture Investor
    ProQuest Investments

By posting a comment, you agree to our terms and conditions.